AccurEdit is a biopharmaceutical company focused on advancing in vivo gene editing therapies. It operates in the field of genome editing medicine, with platforms and pipelines aimed at safe and targeted gene modification in humans, including systemic delivery and RNA synthesis workflows. The company highlights progress in China and the United States, pursuing regulatory recognition and clinical translation of its gene editing therapies.
No recent deals for this company.